Media Report
Press Release
-
CANbridge Pharmaceuticals Enters into Duchenne Muscular Dystrophy Gene Therapy Research Agreement with University of Washington School of Medicine
Nov 1, 2021 -
First Patient Dosed in CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China
October 26，2021 -
CANbridge Pharmaceuticals Enters into Exclusive Worldwide Research Collaboration and Licensing Agreement with Scriptr Global for Stitchr™ RNA Assembly Technology to Develop Gene Therapy Product Targeting Dystrophinopathies
CANbridge to Have Exclusive Worldwide Rights to Product
Oct 25, 2021 -
CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher DiseaseOctober 20, 2021
-
CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted by China’s National Medical Products AdministrationAug 2, 2021
-
CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)JUL 15，2021
-
CANbridge Pharmaceuticals CEO, James Xue, Named as Termeer Foundation MentorMAY 12, 2021
-
Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver DiseasesAPR 29, 2021
-
CANbridge Pharmaceuticals Announces Strategic Collaboration with LogicBio Therapeutics and Licenses to Gene Delivery and Editing PlatformsAPR 27, 2021